Press Releases

Dow ranked #79 on the list, moving up 10 places from last year, and is the highest-ranking manufacturing company to make the list.

MIDLAND, MI / ACCESSWIRE / May 14, 2024 / Great Place To Work� and Fortune have recognized Dow (NYSE: DOW) as one of the Fortune 100 Best Companies to Work For� for the fourth consecutive year, moving up 10 places from #89 last year to #79.

Dow is also the only materials science company to be recognized and the highest-ranking of the four... (continue reading...)

Legal Action Cites Financial and Reputational Damage Created by Adalytics' Inaccurate Paper Targeting Black-Owned Direct Digital Holdings' Inclusive Marketplace

HOUSTON, May 14, 2024 /PRNewswire/ -- Colossus Media LLC ("Colossus SSP" or the "Company"), the inclusive supply-side advertising platform, today filed a civil lawsuit against Adalytics Research LLC of New York City for defamation, injurious falsehood and false advertising.

The suit alleges that Adalytics... (continue reading...)

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- MEACOR Inc. is pleased to announce the successful closing of its $15 million Series A funding round. This substantial investment supports MEACOR’s mission to offer a novel transcatheter approach for the treatment of mitral and tricuspid valve regurgitation.

“This is a pivotal moment for MEACOR,” said Toufic Azar, CEO and co-founder. “This funding round underscores the potential of our technology to enhance valvular... (continue reading...)

BURNABY, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- L’Arche Greater Vancouver gratefully announces that its We All Belong campaign has received a second major donation from the same family Foundation. In 2019, shortly after L’Arche launched its redevelopment campaign, the Morris and Helen Belkin Foundation donated $500,000 to start the campaign. This donation was the largest L’Arche had ever received. On May 1, 2024, they added a second gift of... (continue reading...)

SEONGNAM-SI, South Korea--(BUSINESS WIRE)-- AriBio Co., Ltd. (AriBio), a biotech company dedicated to pioneering treatments for neurodegenerative diseases, announces approval of the Investigational New Drug (IND) application by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the initiation of the Phase 3 Polaris-AD trial in China of AR1001 in early Alzheimer’s Disease (AD) on May 11th, 2024.

The Phase 3... (continue reading...)